Patents by Inventor Bent Präfke

Bent Präfke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11912701
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 27, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11858927
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 2, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20220281864
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 8, 2022
    Inventors: Wolfgang ALBRECHT, Stefan LAUFER, Roland SELIG, Phillip KLÖVEKORN, Bent PRÄFKE
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20210078995
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: January 30, 2019
    Publication date: March 18, 2021
    Inventors: Bent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20190365723
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke